Sustaining a high growth rate requires tumors to exploit resources in their microenvironment. One example of this is the extensive angiogenesis that is a typical feature of high-grade gliomas. Here, we show that expression of the constitutively active mutant epidermal growth factor receptor, DEGFR (EGFRvIII, EGFR*, de2-7EGFR) is associated with significantly higher expression levels of the pro-angiogenic factor interleukin (IL)-8 in human glioma specimens and glioma stem cells. Furthermore, the ectopic expression of DEGFR in different glioma cell lines caused up to 60-fold increases in the secretion of IL-8. Xenografts of these cells exhibit increased neovascularization, which is not elicited by cells overexpressing wildtype (wt)EGFR or DEGFR with an additional kinase domain mutation. Analysis of the regulation of IL-8 by site-directed mutagenesis of its promoter showed that DEGFR regulates its expression through the transcription factors nuclear factor (NF)-jB, activator protein 1 (AP-1) and CCAAT/enhancer binding protein (C/EBP). Glioma cells overexpressing DEGFR showed constitutive activation and DNA binding of NF-jB, overexpression of c-Jun and activation of its upstream kinase c-Jun N-terminal kinase (JNK) and overexpression of C/EBPb. Selective pharmacological or genetic targeting of the NF-jB or AP-1 pathways efficiently blocked promoter activity and secretion of IL-8. Moreover, RNA interference-mediated knock-down of either IL-8 or the NF-jB subunit p65, in DEGFR-expressing cells attenuated their ability to form tumors and to induce angiogenesis when injected subcutaneously into nude mice. On the contrary, the overexpression of IL-8 in glioma cells lacking DEGFR potently enhanced their tumorigenicity and produced highly vascularized tumors, suggesting the importance of this cytokine and its transcription regulators in promoting glioma angiogenesis and tumor growth.
Sustaining a high growth rate requires tumors to exploit resources in their microenvironment. One example of this is the extensive angiogenesis that is a typical feature of high-grade gliomas. Here, we show that expression of the constitutively active mutant epidermal growth factor receptor, DEGFR (EGFRvIII, EGFR*, de2-7EGFR) is associated with significantly higher expression levels of the pro-angiogenic factor interleukin (IL)-8 in human glioma specimens and glioma stem cells. Furthermore, the ectopic expression of DEGFR in different glioma cell lines caused up to 60-fold increases in the secretion of IL-8. Xenografts of these cells exhibit increased neovascularization, which is not elicited by cells overexpressing wildtype (wt)EGFR or DEGFR with an additional kinase domain mutation. Analysis of the regulation of IL-8 by site-directed mutagenesis of its promoter showed that DEGFR regulates its expression through the transcription factors nuclear factor (NF)-jB, activator protein 1 (AP-1) and CCAAT/enhancer binding protein (C/EBP). Glioma cells overexpressing DEGFR showed constitutive activation and DNA binding of NF-jB, overexpression of c-Jun and activation of its upstream kinase c-Jun N-terminal kinase (JNK) and overexpression of C/EBPb. Selective pharmacological or genetic targeting of the NF-jB or AP-1 pathways efficiently blocked promoter activity and secretion of IL-8. Moreover, RNA interference-mediated knock-down of either IL-8 or the NF-jB subunit p65, in DEGFR-expressing cells attenuated their ability to form tumors and to induce angiogenesis when injected subcutaneously into nude mice. On the contrary, the overexpression of IL-8 in glioma cells lacking DEGFR potently enhanced their tumorigenicity and produced highly vascularized tumors, suggesting the importance ofIntroduction Amplification of the epidermal growth factor (EGFR) is present in almost 50% of glioblastomas (GBMs) (Hurtt et al., 1992; Jaros et al., 1992; Schlegel et al., 1994) , and is often associated with activating mutations such as the deletion of exons 2-7 (EGFRvIII, EGFRde2-7, hereafter referred to as DEGFR) that generates a truncated receptor that is unable to bind its ligands but is constitutively active (Huang et al., 1997; Narita et al., 2002) and correlates with poor prognosis (Shinojima et al., 2003; Heimberger et al., 2005) . The ability of DEGFR to enhance the tumorigenic properties of human gliomas has been clearly demonstrated in animal models: human glioma cells, or primary mouse astrocytes, engineered to overexpress DEGFR, when injected either intracranially or subcutaneously, form tumors much faster than their respective parental cell lines (Huang et al., 1997; Holland et al., 1998; Bachoo et al., 2002) . Although it has been previously shown that DEGFR is constitutively phosphorylated and bound to Shc-Grb2-Ras and phosphoinositide-3-kinase (PI-3K) (Prigent et al., 1996; Huang et al., 1997) , many aspects of DEGFR signaling have not yet been completely defined. Although there is evidence that DEGFR induces transcriptional activation of selected genes (Inda et al., 2010) , the downstream effectors responsible for DEGFR-mediated enhanced tumor growth have not been fully elucidated, nor have specific transcription factors driving the DEGFR phenotype been identified.
The wild-type EGFR (wtEGFR) is known to activate a variety of transcription factors, including signal transducers and activators of transcriptions (Zhong et al., 1994) , AP-1 (Malliri et al., 1998) and nuclear factor (NF)-kB (Biswas et al., 2000) . The NF-kB family of transcription factors includes seven proteins sharing a DNA-binding domain known as the REL homology domain (Li and Verma, 2002 ) that, in their active form, associate to form homo-or heterodimers that bind to a common sequence motif known as the kB site. In the absence of stimulation, NF-kB factors are held in the cytoplasm by inhibitory subunits called IkB (Li and Verma, 2002) . The stimulation produced by some inflammatory cytokines activates the IkB kinase complex, which phosphorylates IkB promoting its subsequent targeting to the proteasome, and thus the release of the active NF-kB.
NF-kB has been implicated primarily in hematological malignancies, but also appears to have a role in solid tumors such as breast, ovarian, colorectal, gastric cancers and others (Lee et al., 2007) . Its role in tumor development likely results from its ability to suppress apoptosis through the activation of anti-apoptotic genes such as cellular inhibitors of apoptosis, cellular FLICElike inhibitory protein (c-FLIP), B-cell lymphoma 2 (BCL-2) and BCL-X L (Karin and Lin, 2002) . Additional evidence that NF-kB has a role in tumorigenesis derives from its ability to induce the expression of many cytokines and genes involved in immune responses and in cell proliferation (interleukin (IL)-2, granulocytemacrophage colony-stimulating factor, CD40L and G1 cyclins), angiogenesis (IL-8 and vascular endothelial growth factor (VEGF)) and metastasis (matrix metalloproteinases) . Although it was suggested that EGFR induces NF-kB activation, and this pathway is important in the maintenance of tumors bearing amplification/activation of EGFR or others members of the ErbB family (Biswas et al., 2000) , the molecular mechanisms linking EGFR with NF-kB are not completely understood.
The AP-1 family of transcription factors is composed of a wide variety of dimeric basic region-leucine zipper proteins belonging to the Jun, Fos, Maf and ATF subfamilies, which are regulated at the gene expression level, at the protein level through modification by direct phosphorylation from mitogen-activated protein (MAP) kinases, or by interaction with other transcription factors (Whitmarsh and Davis, 1996) . Several AP-1 proteins can transform cells in vitro simply by overexpression (Jochum et al., 2001) and have been implicated in the development of various tumors, in particular those of epithelial origin (Wang et al., 1991; Young et al., 1999) . The AP-1 proteins are the main activators downstream of MAP kinases, thus their activity is typically increased by receptor tyrosine kinase stimulation. However, the signaling events causing activation of AP-1 are not always identical and may depend on several cell-specific factors including differential expression/activation of MAP kinases (Bancroft et al., 2002; Sparmann and Bar-Sagi, 2004 ) and the composition of AP-1 dimers themselves (van Dam and Castellazzi, 2001) .
We recently reported that the secretion of IL-6 is markedly elevated in glioma cell lines and glioma stem cells that overexpress DEGFR and its expression is also increased in human glioma samples where the DEGFR variant is present (Inda et al., 2010) . Here, we demonstrate that DEGFR also promotes the expression of high levels of IL-8 in glioma clinical samples and cell lines. This overexpression is mediated at the transcriptional level by NF-kB, AP-1 and C/EBP, which show constitutive activation dependent on the kinase activity of DEGFR. We further show that blocking this pathway by RNA interference knock-down of either NF-kB or IL-8 in DEGFR-positive cells abrogated tumor angiogenesis with a concomitant reduction in tumor formation, while overexpression of IL-8 in DEGFR-negative cells significantly enhanced tumorigenicity and associated blood vessel formation. Our results also show NF-kB to be an important mediator of DEGFR enhancement of tumorigenicity in glioma, as direct short hairpin RNA (shRNA) knock-down of NF-kB also inhibited the in vivo tumor growth of cells overexpressing DEGFR.
Results

GBM cell lines overexpressing DEGFR form highly vascularized tumors
The presence of an abundant and disorganized vasculature is believed to be an important determinant of the aggressive phenotype of high-grade gliomas (Maher et al., 2001) . To identify a potential link between angiogenesis and the amplification/mutation of EGFR commonly observed in gliomas, we analyzed the vasculature in mouse intracranial xenografts derived from U87MG (U87Par) glioma cells and compared with tumors derived from the same cells engineered to express tumorassociated levels of DEGFR (U87D), wild-type EGFR (U87wt) and control kinase-dead DEGFR (U87DK). Immunohistochemical staining for the endothelial cell and pericyte marker CD31 in xenografts derived from DEGFR cells demonstrated the highest vessel density throughout the tumor mass, compared with tumors derived from all other U87 lines as determined by quantification of the area occupied by vessels (Figure 1a ).
IL-8 is upregulated in GBM cell lines overexpressing DEGFR It is known that gliomas respond to hypoxic conditions by upregulating VEGF and thus stimulate the formation of blood vessels. However, no differences in VEGF secretion were observed between U87D and U87Par cells in vitro (Figure 1b) suggesting that there might be other factors specifically induced in the former responsible for the markedly different angiogenic phenotype observed in tumors derived from those cells compared with the other U87 derivatives. To identify such secreted factors we analyzed the conditioned media (CM) of U87 glioma cell line derivatives using a cytokine array that qualitatively detects 79 human cytokines and growth factors in the supernatants of these cultured cells. Among these, IL-8 (also known as CXCL8) was the most upregulated molecule in U87D CM compared with CM from U87wt, control kinase-dead DEGFR-expressing (U87DK) or parental cell lines (data not shown). Quantification of IL-8 by enzyme-linked immunosorbent assay (ELISA) showed that its expression varied among cell lines (from 218.42 to 4921.7 pg/ml), however, all DEGFR-engineered cells had a significant increase in IL-8 secretion and expression when compared with their isogenic partners that did not express the receptor. This varied from approximately 2-fold for LNZ-308 to up to 60-fold more for U87MG (Figure 1c ). In no cell line did the overexpression of wtEGFR or DK alone induce an increase in IL-8 secretion (Figure 1c ). Analysis by realtime quantitative PCR of IL-8 RNA expression in U87MG and U178MG cell line derivatives confirmed the results obtained by ELISA (Figure 1d ), thus indicating that the increased IL-8 production is the result of a transcriptional activation of the IL-8 gene. Furthermore, real-time PCR demonstrated significantly higher levels of IL-8 expression in DEGFR-positive human GBM clinical samples, as well as tumor spheres derived from GBM specimens than in those without DEGFR expression (Po0.05) (Figure 1e ).
IL-8 contributes to DEGFR-promoted angiogenesis and tumor growth Ectopic expression of DEGFR in GBM cell lines dramatically increases their ability to grow as xenografts (Huang et al., 1997) . To test the contribution of IL-8 to this DEGFR-mediated enhancement of tumorigenesis, we inhibited its expression in U87D cells by small interfering RNA (siRNA) transfection (Figure 2a ). There was no significant effect on cell proliferation 
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As durability tests with the transfected siRNAs suggest that the effect of the siRNA-mediated knockdown would have diminished by 7 days post injection (data not shown), we interpret this modest reduction in angiogenesis as a reflection of IL-8 expression recovery in the tumors. As a complementary means to test the effect of acute IL-8 knockdown on angiogenesis, we performed an in vitro HUVEC tube formation assay using CM from U87D cells freshly transfected with GFP or IL-8 siRNAs. The ability of U87D CM to induce tube formation was strongly impaired when the IL-8 siRNA was fully effective (Figure 2f ), supporting the idea that IL-8 overexpression might contribute to DEGFR-driven enhanced angiogenesis.
IL-8 gene expression is regulated by NF-kB, AP-1 and C/EBP-binding sequences
To analyze the transcriptional regulation of IL-8, we isolated its promoter and inserted it into a reporter plasmid to drive the expression of the luciferase gene. Point mutations in the NF-kB, AP-1 and C/EBPbinding sites, previously reported as important regulators of IL-8 transcription (Matsusaka et al., 1993; Holtmann et al., 1999) were also introduced (Figure 3a) , and the activity of each construct was evaluated by luciferase assays in U87D cells and compared with U87Par. As expected, we found that the activity of the wild-type IL-8 promoter was significantly increased in U87D (Figure 3b ; Po0.01). Mutation of either the AP-1 or the C/EBP sites caused a significant reduction in reporter gene expression (Po0.001), while mutation of the NF-kB site completely abolished the promoter activity (Figure 3b ; Po0.001).
NF-kB, AP-1, C/EBP are activated in DEGFR cells As full activation of NF-kB transcriptional activity requires phosphorylation of its p65 subunit at serine 536 (Jiang et al., 2003) , we interrogated the phosphorylation of this residue and found that it was increased in DEGFR cells regardless of the presence of serum in the culture medium, suggesting it is constitutive lyactivatedin these cells (Figure 4a ). No increase in phosphorylation of p65 was observed in cells overexpressing wtEGFR even in the presence of serum. To confirm that p65 phosphorylation corresponds to increased transcriptional activity of NF-kB in DEGFR cells, we performed a reporter assay using a construct containing the firefly luciferase gene under the control of four copies of the NF-kB consensus sequence. U87D cells showed significantly increased luciferase activity (Po0.001), indicating that NF-kB target genes could be upregulated in these cells (Figure 4b ). These results were further validated by analyzing the binding of nuclear NF-kB in U87 cell derivatives to a radiolabeled oligonucleotide containing the NF-kB consensus sequence: the increased binding observed in U87D was ablated for an IkB construct mutated in all activating serines and threonines to alanines that prevents NF-kB from shuttling to the nucleus (known as IkB superrepressor, IkBsr) (Van Antwerp et al., 1996) (Figure 4c ).
Similar results were obtained by using AP-1 or C/EBP reporter plasmids: the activity measured by luciferase assay was increased in DEGFR cells (Po0.05), but not in wtEGFR or DK cells (Figures 4d and f) . We then analyzed the AP-1 pathway both at the level of upstream kinases and transcription factor expression in these isogenic cell lines. Western blots for the phosphorylated forms of the different mitogen-activated protein kinase (MAPK) classes revealed increased c-Jun N-terminal kinase (JNK) activity in unstimulated DEGFR cells (Figure 4e ), but not ERK or p38 (data not shown). Moreover, AP-1 was also induced in DEGFR cells at the expression level, as demonstrated by the upregulation of c-Jun, the substrate of JNK (Figure 4e) . A similar mechanism of DEGFR-dependent regulation of the C/EBPb transcription factor was also observed in U87 cells (Figure 4g ).
The secretion of IL-8 is reduced by inhibitors of NF-kB and JNK To verify whether NF-kB and AP-1 pathways are required by DEGFR cells to produce high levels of IL-8, we analyzed its secretion in serum-starved cells treated with pharmacological inhibitors that target the two pathways at different levels. Treatment of U87D cells with BAY11-7082, an inhibitor of IkB phosphorylation, significantly (Po0.001) reduced IL-8 secretion ( Figure 5a ). As AP-1 activity is regulated post-transcriptionally by MAPK-mediated phosphorylation, we EGFRvIII promotes angiogenesis by NF-jB/IL-8 R Bonavia et al next assessed whether DEGFR activates AP-1 through MAPKs and to identify which MAPK was involved. We treated serum-starved U87D cells with selective inhibitors for each MAPK-class for 24 h and then analyzed the secretion of IL-8 by ELISA. No effect on IL-8 secretion was observed after treatment with the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059 (10 mM) or the p38 inhibitor SB203580 (10 mM) (Figure 5b ). In contrast, a significant reduction of IL-8 secretion was achieved when U87D cells were treated with the JNK inhibitor SP600125 (10 mM) (Figure 5b ; Po0.05), confirming the results obtained by western blotting (Figure 4e ).
IL-8 promoter activity is reduced by blocking NF-kB and JNK/c-Jun pathways
We next sought to modulate IL-8 promoter activity by transducing negative regulators of NF-kB and JNK/ EGFRvIII promotes angiogenesis by NF-jB/IL-8 R Bonavia et al AP-1 into DEGFR-expressing cells. The transcription of the luciferase gene driven by this promoter was reduced to parental levels by co-expression of IkBsr (Figure 5c ). Similarly, secretion of IL-8 was significantly reduced in DEGFR-expressing cells stably infected with IkBsr (Po0.01) (Supplementary Figure 4) . The activity of IL-8 promoter was also reduced by the co-expression of a dominant-negative c-Jun construct in which the amino acids 3-122 of the transactivation domain were deleted (TAM67, c-Jundn) (Brown et al., 1993) (Figure 5d ).
Assays performed with NF-kB and AP-1 reporter constructs to corroborate the effective blockade of these pathways, mirrored the results obtained with the IL-8 construct (Figures 5c and d) .
IL-8 transcription is regulated in part by Ras but not by PI-3K It has been proposed that Ras is the common upstream regulator of NF-kB and AP-1, through the activation of PI-3K and Raf or Rac (Sparmann and Bar-Sagi, 2004) . Moreover, Ras is activated by DEGFR (Prigent et al., 1996) , thus a single signaling pathway emanating from DEGFR might explain the activation of both transcription factors. To test this hypothesis, we analyzed the activity of the IL-8 promoter in DEGFR-expressing cells transduced with a retrovirus-expressing dominant-negative Ras (Ras17N) . Similar experiments were also performed using a dominant-negative PI-3K p85 subunit lacking its SH2 domain (p85DSH2), as well as IkBsr. IL-8 promoter activity was reduced by all constructs, except for p85DSH2 (Figure 6a ). Analysis of the phosphorylation of Akt revealed that p85DSH2 was only partially effective in blocking the PI-3K pathway (Figure 6b ). Based on this result, we further assessed the involvement of PI-3K in the regulation of IL-8 by using the PI-3K inhibitor, LY294002. Although the treatment of U87D with this inhibitor efficiently blocked Akt activation for up to 24 h (Figure 6d ), no effect on IL-8 secretion was observed (Figure 6c ), suggesting that the induction of this cytokine is independent of PI-3K activity. Furthermore, in reporter assays designed to elucidate interconnections between Ras and the other pathways, we found that Ras17N was able to reduce AP-1, but not NF-kB activity inU87D (Figure 6e) , and, similarly, the JNK inhibitor SP600125 blocked the activity of the AP-1 but not of the NF-kB or C/EBP reporters ( Figure 6f ). These data indicate that Ras regulates IL-8 transcription solely through the activation of the JNK/AP-1 pathway, while it does not affect the other transcription factors identified. 
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Blockade of NF-kB suppresses DEGFR-promoted glioma angiogenesis and tumor growth As NF-kB appears to have a prominent role among the transcriptional regulators of IL-8 expression (Figure 3b) , we tested the effect of NF-kB suppression on DEGFR tumorigenicity by shRNA-mediated knock-down. A panel of shRNAs against the p65 NF-kB subunit was tested in vitro in U87D cells, showing that 3 out of 4 were able to suppress p65 expression (Figure 7a ). Subcutaneous injection into nude mice of U87D cell population stably transduced with shRNA #1 resulted in a significantly (Po0.001) reduced tumor growth when compared with U87D or U87D transduced with a shRNA against GFP ( Figure 7b ). As expected, the constitutive abrogation of NF-kB signaling had a profound impact on the tumor vasculature as samples from p65 shRNA cells showed a vascular density reduced by 50% compared with control tumors (Supplementary Figure 5 ). To confirm the effect of NF-kB on IL-8 expression, we quantified IL-8 in the same tumor lysates and observed decreased levels of this cytokine in p65 knocked-down xenografts (Figure 7c ; Po0.01). Together, these results show an important role for NF-kB activation and IL-8 secretion in gliomas expressing DEGFR.
Discussion
Here, we show that a complex network of signals originating from the highly tumorigenic DEGFR is able to activate multiple pathways that act synergistically to potentiate the production of IL-8, a pro-inflammatory cytokine of proven importance in the progression of high-grade gliomas (Garkavtsev et al., 2004) . The transcription factors activated by DEGFR belong to three distinct families: NF-kB, AP-1 and C/EBP. 
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The role of IL-8 in glioma has been under investigation for several years (Brat et al., 2005) . Although in other cancers it has been demonstrated that IL-8 can directly stimulate the proliferation of tumor cells (Brew et al., 2000; Takamori et al., 2000; Yao et al., 2007) , in gliomas this autocrine effect is unlikely, based on the low expression levels of its receptors in glioma cells (Zhou et al., 2002) . Our data support this hypothesis, as transfection of U87D cells with IL-8 siRNAs did not greatly alter cell proliferation in vitro ( Supplementary  Figure 1) and IL-8 stimulation of U87 cells was not able to produce intracellular signaling such as ERK or Akt phosphorylation (data not shown). Rather, IL-8 may promote tumor growth by altering the microenvironment through the stimulation of angiogenesis (Garkavtsev et al., 2004) . Although the uniqueness and indispensability of VEGF in regulating key events during physiological angiogenesis has been demonstrated (Ferrara et al., 1996) , it is also true that some unrelated growth factors are either able to potently enhance its activity (Cao et al., 2003) or are even required for particular steps in the process (Hellstrom et al., 2007) . In this context, the role of IL-8 remains controversial, because although its involvement in angiogenesis seems to be well established, the molecular mechanism and the target cells are still completely obscure. Here, we provide evidence that the ectopic overexpression of IL-8 alone in cell lines with low basal VEGF secretion can induce a switch to a more tumorigenic and more angiogenic phenotype when injected in nude mice. This suggests that in human GBMs any event that would cause IL-8 upregulation might be sufficient to enhance the pro-angiogenic phenotype, and could represent a mechanism exploited by these tumors to circumvent therapies based on anti-VEGF antibodies, even after an initial response to the treatment (Norden et al., 2008) . We demonstrated a correlation between DEGFR expression and IL-8 upregulation in GBM clinical samples, GBM tumor spheres and, that DEGFR ectopic expression in GBM cell lines induces IL-8, but not VEGF, production and secretion. In other contexts, both wild-type and mutant EGFR have been found to direct VEGF expression (Gille et al., 1997; Petit et al., 1997; Magnus et al., 2010) . However, although U87 cells secrete low levels of VEGF in vitro, this basal VEGF secretion could be required in vivo to obtain angiogenesis. The combined effect of constitutive EGFR signaling and hypoxic conditions on the expression of VEGF and IL-8, and the relative importance of the two cytokines, individually and together, needs to be further addressed. Our results illustrate that, in absence of other signaling inputs, signaling generated by DEGFR is able to produce an abundance of a pro-angiogenic factor such as IL-8, which therefore might represent in DEGFR-positive GBMs an additional element acting to potentiate the well-known hypoxia-VEGF axis. We showed that the inhibition of IL-8 was able to reduce the stimulatory activity of U87D CM on endothelial cells in vitro. In this context, the negligible amounts of VEGF secreted by U87 cells allowed us to highlight the differences between U87Dwith normal or reduced IL-8 secretion and to attribute DEGFR-mediated stimulation of endothelial tube formation to IL-8. However, more thorough experiments will be required to better assess the contribution of IL-8 on tumor angiogenesis in vivo and the possible existence of other factors specifically upregulated by DEGFR.
Prior studies have shown that EGFR-mediated activation of NF-kB required PI-3K/Akt signaling (Bancroft et al., 2002; Le Page et al., 2005) , which is supported by evidence that Akt can interact with IkB kinase complex-a (Romashkova and Makarov, 1999 ). 
However, it has also been suggested that alternative mechanisms might exist for EGF-induced NF-kB activation, independent of IkB kinase complexes (Garkavtsev et al., 2004; Weissenberger et al., 2004) . This model requires the activity of NF-kB inducing kinase (NIK), which has been found to be a component of all ErbB family receptors signaling complexes and to be required for NF-kB activation induced by EGF or heregulins (Chen et al., 2003) . Our data support a PI-3K-independent activation of NF-kB downstream of DEGFR based on the inability of LY294002, a potent inhibitor of PI-3K, to reduce the secretion of IL-8, and dominant-negative PI-3K incapable of blocking the IL-8 promoter activity. Further studies are required to elucidate whether this unique signaling is a common feature of glioma cells or is specifically driven by DEGFR signaling.
In the presence of growth factors, Ras can activate MEKK1, either directly or indirectly through PI-3K and Rac1 or Cdc42Hs. MEKK1 in turn phosphorylates the MAPK kinases, MKK4 and MKK7, which then activate JNK (Kyriakis and Avruch, 2001) . JNK has been found to be activated in cells transfected with DEGFR, and it was proposed that its activation is mediated by PI-3K (Antonyak et al., 1998) . Our data suggest a different link between DEGFR and JNK, as PI-3K inhibition did not affect either the secretion of IL-8 (Figure 6 ) or JNK activation (data not shown). As the JNK inhibitor was quite effective in decreasing IL-8 secretion, we hypothesize that JNK activity is important for the overexpression of this cytokine, although we cannot exclude the possibility that the upregulation of c-Jun alone might be sufficient to ensure basal constitutive AP-1 activity or that in DEGFRpositive cells other activating mechanisms might exist, for example, through MEK/ERK. The reduction in transcriptional activity observed when introducing a dominant-negative Ras is similar to that obtained with a dominant-negative c-Jun, but was less effective than IkBsr. Moreover, Ras17N and the JNK inhibitor SP600125 reduced AP-1 reporter activity to a similar extent, while they were both ineffective on NF-kB. Collectively, these data indicate the existence of a Ras/ JNK/AP-1 pathway in U87D cells, while NF-kB activation seems to be independent of Ras or PI-3K. It is noteworthy that VEGF can also be regulated by Rasin GBM under both normoxic and hypoxic conditions (Feldkamp et al., 1999) , pointing at this pathway as a key regulator of angiogenic events in astrocytic tumors.
Our data show that ectopic expression of IL-8 in human glioma cell lines dramatically increases their ability to form tumors in nude mice. Moreover, we demonstrated that IL-8 is an important target of DEGFR signaling, as its knock-down was able to reduce the tumor volume by approximately 50%. In previous work, similar knock-down of IL-6 expression in DEGFR cells, in contrast to these results with IL-8, resulted in no difference in tumor formation when compared with non-transfected cells (Inda et al., 2010) . On the contrary, in IL-6 was able to stimulate the growth of cells overexpressing wtEGFR a paracrine fashion. We hypothesize that, in the scenario of a tumor composed of different cell populations with amplified/ mutated EGFR, as in most clinical samples (Biernat et al., 2004; Nishikawa et al., 2004) , combined therapy targeting the two cytokines might have synergistic efficacy. As the knock-down of the NF-kB p65 subunit produced a stronger impairment in the tumor growth of DEGFR cells than that obtained by knocking-down IL-8, we predict that NF-kB targets are not limited to IL-8. DEGFR cells show a marked resistance to cytotoxic drugs in vitro, mediated through increased expression of Bcl-X L (Nagane et al., 1998) . NF-kB is a well-known regulator of many antiapoptotic genes including Bcl-X L itself (Tsukahara et al., 1999) , but also Bcl-2 and cellular inhibitors of apoptosis (Karin and Lin, 2002) , thus it is possible that NF-kB not only regulates growth promoting cytokines, but also induces an apoptosis-resistant phenotype.
Materials and methods
Cell lines
Glioma cell lines were engineered to overexpress wtEGFR, DEGFR or a dead kinase version of DEGFR as described previously (Nishikawa et al., 1994) . U87Par-IL-8 and U87wt-IL-8 were obtained by transducing U87Par and U87wt, respectively, with a pBabePuro retrovirus expressing the fulllength human IL-8 complementary DNA obtained by reverse transcriptase-PCR, and stably selected.
Plasmids NF-kB and AP-1 reporter plasmids (pNFkB-Luc and pAP1-Luc) were purchased from Clontech (Mountain View, CA, USA). IL-8 promoter was obtained by PCR using human genomic DNA and the following primers: 5 0 -GCGGTACC-GAATTCAGTAACCCAGGCATTATT-3 0 , 5 0 -CCTAGAAG CTTGTGTGCTCTGC-3 0 (À1480 to þ 50). The resulting amplified fragment was sequenced and inserted into the pNFkB-Luc backbone (Clontech). The mutations in AP-1, NF-kB and C/EBP consensus sequences were inserted by PCR using the following oligonucleotides and corresponding reverse primers (point mutations in capital letters): AP-1 5 0 -aagtgtga tgCAGcaggtttgccctgagg-3 0 , C/EBP, 5 0 -ggccatcagAtATCaatcgt ggaatttcc-3 0 and NF-kB 5 0 -ttgcaaatcgtAgaTCttcctctgacataa-3 0 . The full-length human IL-8 complementary DNA was obtained by reverse transcriptase-PCR, sequenced and cloned into the BamHI/SalI sites of pBabePuro. Dominant-negative cJun was obtained by PCR amplification from human fetal complementary DNA to obtain amino acids 123-331 (lacking the transactivation domain) and inserted in the EcoRI/XhoI sites of pCMV-HA (Clontech). The IkBsr construct, consisting of mouse IkB mutated at serines 32, 36, 283, 288 and 293 and threonines 291 and 296 to alanines was a kind gift of Dr Inder Verma (Salk Institute, La Jolla, CA, USA). Dominant-negative PI-3K p85 in which the SH2 domain was deleted (p85DSH2) was a kind gift of Dr Julian Downward. Dominant-negative Ras (Ras17N) was a kind gift of Dr Gerry Boss (UCSD, La Jolla, CA, USA).
Antibodies IL-8 antibodies were purchased from R&D Systems (Minneapolis, MN, USA); NF-kB p65 (total and phospho-Ser536), SAPK/ JNK (total and phospho-Thr183/Tyr185), c-Jun, C/EBPb, phospho-Akt (Ser473) were purchased from Cell Signaling (Beverly, MA, USA). Anti-actin was from Sigma (St Louis, MO, USA). The cytokine array was purchased from Ray Biotech EGFRvIII promotes angiogenesis by NF-jB/IL-8 R Bonavia et al (Norcross, GA, USA) and performed according to the manufacturer's instructions.
Inhibitors BAY11-7082, PD98059, SB203580, SP600125 and LY294002 were purchased from Calbiochem (Rockland, MA, USA).
Luciferase assay Double luciferase assays were used to access the activities of reporter genes. Briefly, cells were seeded in 12-well plates at 10 5 cells per well and the day after were transfected with 200 ng of the indicated reporter plasmid expressing the firefly luciferase and 20 ng of the control plasmid consisting of Renilla luciferase under the control of the Herpes simplex virus thymidine kinase promoter, plus 4 ml of Lipofectamine 2000 per well. When indicated, 500 ng of an additional expression construct, or the same amount of empty vector as control, were added to the mixture. The following day the cells were washed, serum-starved for 24 h and then lysates were prepared. The luciferase activity was measured by using a dual luciferase assay kit (Promega, Madison, WI, USA) and a Tecan Genios Proluminometer (Tecan, Ma¨nnedorf, Switzerland) according to the manufacturer's instructions.
ELISA
Sandwich ELISAs were performed as described previously (Inda et al., 2010) . Briefly, microplates coated overnight with capture antibody were incubated 2 h at room temperature with supernatants from 48-h starved cells, freshly collected and spun to eliminate debris, followed by a similar incubation with the detection antibody. The colorimetric reaction was measured in a microplate reader (Tecan Genios Pro) and the readings were normalized with a four-parameter logistic curve.
Electrophoretic mobility shift assay Cells serum-starved for 48 h and treated as indicated were harvested and resuspended in buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT) supplemented with protease and phosphatase inhibitor mixes (Sigma). The cells were allowed to swell on ice for 15 min, and then Nonidet P-40 was added to a final concentration of 0.1%. The suspension was then vortexed for 10 s, and centrifuged at 5000 g for 10 min. The nuclear pellet was resuspended in buffer B (20 mM HEPES pH 7.9, 400 mM KCl, 1 mM EDTA, 20% glycerol, 1 mM DTT, and protease and phosphatase inhibitors). After 30 min on ice with intermittent mixings, nuclear extracts were cleared at 10 000 g for 5 min at 4 1C and supernatants were collected.
A double-stranded oligonucleotide containing the NF-kB consensus sequence (in capitals) (5 0 -agttgagGGGACTTTCC caggc-3 0 ), purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA), was labeled by using [g-32 P]ATP and T4 polynucleotide kinase and purified by gel filtration on S-200 spin columns (Pharmacia, Piscataway, NJ, USA). Five mg of nuclear extract protein and the labeled oligonucleotide were incubated in 10 mM Tris (pH 7.4), 10 mM EDTA, 0.5% bovine serum albumin, 0.5 M NaCl, 10 mM DTT, 50% glycerol and 1 mg of poly (dI-dC) in a final volume of 10 ml for 30 min at room temperature. The protein-DNA complexes were resolved on 4% polyacrylamide gels and visualized by autoradiography.
Real-time quantitative PCR Total RNA was extracted from 19 human GBM samples and from 9 gliomatumorspheres isolated from GBM patients as described previously (Inda et al., 2010) . Real-time PCR was performed using Maxima SYBR Green qPCR Master mix (Fermentas, Glen Burnie, MD, USA) on an iCycler (Bio-Rad, Hercules, CA, USA) following the manufacturer's instructions. Primers used for IL-8 amplification were: 5 0 -TAAA-CATGACTTCCAAGCTGGCCG-3 0 (forward) and 5 0 -GTGTGGTCCACTCTCAATCACTCT-3 0 (reverse). Primers used for DEGFR and glyceraldehyde 3-phosphate dehydrogenase amplification were the same described previously (Inda et al., 2010) . Glyceraldehyde 3-phosphate dehydrogenase expression was used for normalization and relative quantification using the Ct values was performed for each sample.
RNA interference
A set of 24 siRNAs targeting IL-8 was designed and synthesized on an ABI3900 DNA synthesizer using standard procedures, purified by anion exchange (AEX) high-performance liquid chromatography, and annealed in phosphate-buffered saline. SiRNAs were tested in vitro: U87D cells were seeded in 24-well plates at 48 000 cells per well. The following day, cells were transfected with different concentrations of siRNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) and Opti-MEM (Gibco, Carlsbad, CA, USA). At 24 h after transfection, the medium was changed to serum-free Dulbecco's modified Eagle's medium media, which was collected 48 h after starvation and analyzed for IL-8 secretion by ELISA. Cells non-transfected as well as transfected with a siRNA specific for GFP (5 0 -GCUG ACCCUGAAGUUCAUC-3 0 ) (Dharmacon, Lafayette, CO, USA) were included as negative control. The IL-8 siRNA sequence with chemical modifications follows (lower case letters indicate 2 0 -O-methyl modification at that position; s indicates phosphorothioate linkage; dT indicates deoxythymidine): antisense strand 5 0 -UGGCuAGcAGACuAGGGUUdTsdT-3 0 , sense strand 5 0 -AAcccuAGucuGcuAGccAdTsdT-3 0 . Lentiviral vectors expressing shRNAs were purchased from the Broad Institute (Boston, MA, USA). Viral particles were produced by transient co-transfection of HEK293FT cells with 2 mg of the shRNA construct, 200 ng of vesicular stomatitis virus G protein (VSV-G) and 2 mg of D 8.9 plasmids using Lipofectamine 2000 (Invitrogen). HEK293FT supernatants were collected 48 h after transfection, filtered and applied to U87D cells. Infected cells were selected in medium containing 400 ng/ml of Puromycin.
Tumor engraftment
For intracranial injection, 5 Â 10 5 cells in 5 ml of phosphatebuffered saline were injected into 4-5 weeks old athymic nude mice using a guide-screw system according to the protocol described by Lal et al. (2000) . For subcutaneous injection, the different U87MG cell lines were harvested, suspended in phosphate-buffered saline and injected subcutaneously into the right flank of 4 to 5 weeks old female athymic nude mice (10 6 cells per mouse in 100 ml for U87Par and U87wt, and 5 Â 10 5 cells per mouse in 100 ml for U87D). Tumors were measured periodically with a vernier caliper and tumor volumes were calculated using the formula V ¼ a 2 Â b/2 where apb. Mice were euthanized when tumor volumes reached 1500 mm 3 (subcutaneous) or at the first neurological symptoms (intracranial). For in vivo experiments with IL-8 siRNA, the cells were transfected with 25 nM siRNA as described above, propagated in vitro and injected subcutaneously 3 to 4 days after transfection.
In vitro HUVEC tube formation assay We used an in vitro angiogenesis assay kit (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions. HUVECs were exposed to CM taken from U87D cells 3 days after transfection with GFP or IL-8 siRNA. The tube formation was monitored and captured using an Olympus IX51 fluorescence microscope (Center Valley, PA, USA).
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